Dr. Aman Chauhan, MD
Claim this profileUniversity of Kentucky/Markey Cancer Center
Studies Neuroendocrine Tumors
Studies Carcinoid Tumor
12 reported clinical trials
20 drugs studied
Area of expertise
1Neuroendocrine Tumors
Stage IV
Stage III
2Carcinoid Tumor
Stage IV
Stage III
SSTR positive
Affiliated Hospitals
Clinical Trials Aman Chauhan, MD is currently running
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
Radioactive Drug vs Everolimus
for Neuroendocrine Cancer
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to a peptide (small protein) that targets tumor cells. When this radioactive peptide is injected into the body, it binds to a specific receptor found on some tumor cells. The radioactive peptide builds up in these cells and helps kill the tumor cells without harming normal cells. In this trial 177Lu-DOTATATE is used for PRRT. 177Lu-DOTATATE PRRT may increase the length of time until worsening of the GEPNET compared to the usual approach. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping tumor cells from reproducing and by decreasing blood supply to the tumor cells. Sunitinib and cabozantinib, block certain proteins, which may help keep tumor cells from growing. They may also prevent the growth of new blood vessels that tumors need to grow. Sunitinib malate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Retreating with 177Lu-DOTATATE may work better than everolimus, sunitinib or cabozantinib in shrinking or stabilizing tumors in patients with metastatic and unresectable GEPNET who were previously treated with 177Lu-DOTATATE.
Recruiting1 award Phase 2
More about Aman Chauhan, MD
Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Aman Chauhan, MD has experience with
- Lutetium Lu 177 Dotatate
- Nivolumab
- Triapine
- Everolimus
- Cabozantinib
- Ipilimumab
Breakdown of trials Aman Chauhan, MD has run
Neuroendocrine Tumors
Carcinoid Tumor
Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aman Chauhan, MD specialize in?
Aman Chauhan, MD focuses on Neuroendocrine Tumors and Carcinoid Tumor. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Aman Chauhan, MD currently recruiting for clinical trials?
Yes, Aman Chauhan, MD is currently recruiting for 3 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Aman Chauhan, MD has studied deeply?
Yes, Aman Chauhan, MD has studied treatments such as Lutetium Lu 177 Dotatate, Nivolumab, Triapine.
What is the best way to schedule an appointment with Aman Chauhan, MD?
Apply for one of the trials that Aman Chauhan, MD is conducting.
What is the office address of Aman Chauhan, MD?
The office of Aman Chauhan, MD is located at: University of Kentucky/Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky/Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.